SIGLEC1 and COVID-19: SIGLEC1 expression is induced on APCs upon IFN-α or LPS exposure and increased in myeloid cells of COVID-19 patients (33) Inhibition of Siglec-1 prevents monocytes from adhering to vascular endothelial cells in the early stage of atherosclerosis, and reduces lipid phagocytosis and chemokine secretion of macrophages, alleviating the inflammatory response of established fat streaking lesions (34).